Patents by Inventor Tujin Shi

Tujin Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11619635
    Abstract: Antibody-free processes are disclosed that provide accurate quantification of a wide variety of low-abundance target analytes in complex samples. The processes can employ high-pressure, high-resolution chromatographic separations for analyte enrichment. Intelligent selection of target fractions may be performed via on-line Selected Reaction Monitoring (SRM) or off-line rapid screening of internal standards. Quantification may be performed on individual or multiplexed fractions. Applications include analyses of, e.g., very low abundance proteins or candidate biomarkers in plasma, cell, or tissue samples without the need for affinity-specific reagents.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: April 4, 2023
    Assignee: Battelle Memorial Institute
    Inventors: Tujin Shi, Weijun Qian, Thomas L. Fillmore, Xuefei Sun, Richard D. Smith
  • Publication number: 20220268785
    Abstract: Disclosed are compositions and methods for performing a proteomic analysis. Particularly disclosed are compositions and methods for preparing a sample for quantitative single-cell proteomics.
    Type: Application
    Filed: February 21, 2022
    Publication date: August 25, 2022
    Inventors: Tujin Shi, Huiping Liu, Chia-Feng Tsai, David Scholten, Reta Birhanu Kitata, Carolina Reduzzi
  • Patent number: 10725053
    Abstract: Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.
    Type: Grant
    Filed: December 12, 2017
    Date of Patent: July 28, 2020
    Assignees: Battelle Memorial Institute, University of Washington
    Inventors: Wei-Jun Qian, Tujin Shi, Alvin Y. Liu
  • Publication number: 20180164329
    Abstract: Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.
    Type: Application
    Filed: December 12, 2017
    Publication date: June 14, 2018
    Inventors: Wei-Jun Qian, Tujin Shi, Alvin Y. Liu
  • Publication number: 20160238614
    Abstract: Antibody-free processes are disclosed that provide accurate quantification of a wide variety of low-abundance target analytes in complex samples. The processes can employ high-pressure, high-resolution chromatographic separations for analyte enrichment. Intelligent selection of target fractions may be performed via on-line Selected Reaction Monitoring (SRM) or off-line rapid screening of internal standards. Quantification may be performed on individual or multiplexed fractions. Applications include analyses of, e.g., very low abundance proteins or candidate biomarkers in plasma, cell, or tissue samples without the need for affinity-specific reagents.
    Type: Application
    Filed: November 23, 2015
    Publication date: August 18, 2016
    Applicant: BATTELLE MEMORIAL INSTITUTE
    Inventors: TUJIN SHI, WEIJUN QIAN, THOMAS L. FILLMORE, XUEFEI SUN, RICHARD D. SMITH
  • Publication number: 20140194304
    Abstract: Antibody-free processes are disclosed that provide accurate quantification of a wide variety of low-abundance target analytes in complex samples. The processes can employ high-pressure, high-resolution chromatographic separations for analyte enrichment. Intelligent selection of target fractions may be performed via on-line Selected Reaction Monitoring (SRM) or off-line rapid screening of internal standards. Quantification may be performed on individual or multiplexed fractions. Applications include analyses of, e.g., very low abundance proteins or candidate biomarkers in plasma, cell, or tissue samples without the need for affinity-specific reagents.
    Type: Application
    Filed: January 8, 2013
    Publication date: July 10, 2014
    Applicant: BATTELLE MEMORIAL INSTITUTE
    Inventors: Tujin Shi, Weijun Qian, Thomas L. Fillmore, Xuefei Sun, Richard D. Smith